Clinical Cancer Trials

HSE West North West / University of Galway Cancer Network



| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigator | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------------|----------------|---|--|--------------------------|----------------|--|---|----------------|--|-------------------------------|
| GUH SUH | Gynaecological | XPORT- EC-042 | A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild- Type, Advanced or Recurrent Endometrial Carcinoma | Open to recruitment | Clinical Trial | Dr Michael Martin Sligo Dr Michael McCarthy Galway | Sligo: Margaret1.Burke@hse.ie Galway: marian.jennings@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05611931 | Results not yet available |
| GUH | Breast | Wavelia | A Stage 2 Open-label, Single Site, Pilot Clinical Investigation to Assess the Detectability and Sizing of Invasive Breast Cancers, the Detectability of Benign Breast Lesions, as well as the Differentiation between Malignant and Benign Breast Lesions using the Wavelia #2 Microwave Breast Imaging System | Closed to recruitment | Clinical Trial | Professor Michael Kerin | olive.forde@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/wavelia/ | Results not yet available |
| GUH | Breast | UCARE | Understanding Cardiac Events in Breast Cancer (UCARE) | Closed to recruitment | Clinical Trial | Professor Aoife Lowery | GrainneB.McDonnell@hse.ie and olive.forde@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/ucare-ts | Results not yet available |
| GUH | Breast | TRIO 045 | A Phase III, RANDOMIZED, Open-label, Multicenter Study Evaluating the Efficacy AND Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine MONotherapy in Patients with ESTROGEN RECEPTOR POSITIVe, Her2-negative EARLY Breast Cancer | Closed to recruitment | Clinical Trial | Professor Maccon Keane | alyssa.paz@hse.ie | 091- 524222 | https://www.clinicaltrials.gov/ study/NCT04961996 | Results not yet available |
| GUH | Lung | Regeneron 3767- ONC-2011 Melanoma | A Phase 3 Trial of Fianlimab (REGN3767, anti-LAG-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma) | Open to recruitment | Clincial Trial | Professor Paul Donnellan | marian.jennings@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/r3767-onc-2011/ | Results not yet available |
| GUH | Melanoma | Regeneron 2810- ONC-1788 Squamous Cell Carcinoma | A Randomized, Placebo-Controlled, Double- Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patient with High-risk Cutaneous Squamous Cell Carcinoma | Closed to recruitment | Clinical trial | Professor Paul Donnellan | marian.jennings@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/r2810-onc-1788/ | Results not yet available |

| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigator | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------|----------------|------------------------------------|--|-----------------------|----------------|-----------------------------|--|----------------|---|-------------------------------|
| GUH | Melanoma | R3767- ONC-2055 | A Phase 3 trial of Fianlimab (Anti Lag 3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients with completely Resected High Risk Melanoma | Open to recruitment | Clinical Trial | Professor Paul Donnellan | marian.jennings@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/r3767-onc-2055/ | Results not yet available |
| GUH | Ovary | Prima | A Phase 3, Randomised, Double-Blind, Placebo Controlled Multicentre Study Of Niraparib Maintenance Treatment In Patients With Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy | Closed to recruitment | Clinical trial | Professor Paul Donnellan | paul.donnellan@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT02655016 | Results not yet available |
| GUH | Prostate | Peace | A prospective randomised phase 3 study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patients with metastatic hormone-naïve prostate cancer | Closed to recruitment | Clinical trial | Professor Cormac Small | emma.stone@universityofgalw ay.ie | 091- 524222 | | Results not yet available |
| GUH | Breast | Oasis-4 | A double-blind, randomized, placebo- controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms induced by adjuvant endocrine thearpy, over 52 weeks in women with, or a high risk for developing hormone-receptor positive breast cancer | Closed to recruitment | Clinical trial | Professor Maccon Keane | marian.jennings@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05587296 | Results not yet available |
| GUH | Lung | NeoCOAS T- 2/D9077C0 0001 | Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer (NeoCOAST-2) | Open to recruitment | Clinical Trial | Dr Silvie Blazkova | olive.forde@hse.ie and alyssa.paz@hse.ie | 091- 524222 | https://www.clinicaltrials.gov/ study/NCT05061550 | Results not yet available |
| GUH | Myeloma | MAIA | Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy | Closed to recruitment | Clinical Trial | Professor Amjad Hayat | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT02252172 | Results not yet available |
| GUH | Lymphoma | INC MOR 208 305 Firmmind | A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Open to recruitment | Clinical Trial | Professor Amjad Hayat | michelleb.hennessy@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/firmmind-incmor0208- 305/ | Results not yet available |

| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigator | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------|----------------|------------------|--|-----------------------|---------------------------|---|--|----------------|--|-------------------------------|
| GUH | AML | Hovon 150 | A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy. | Closed to recruitment | Clinical Trial | Professor Janusz Krawczyk | Dorota.Matczuk@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/hovon-150/ | Results not yet available |
| GUH | Myeloma | GMI-1271- 301 | A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia | Closed to recruitment | Clinical Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://www.clinicaltrials.gov/ study/NCT03616470 | Results not yet available |
| GUH | CML | Enest Freedom | A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment. | Closed to recruitment | Clinical Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT01784068 | Results not yet available |
| GUH | Myeloma | MajesTEC- 4 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Open to recruitment | Clinical Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/majestec-4/ | Results not yet available |
| GUH | Breast | EMBER-4 | J2J-MC-JZLH "A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence" | Open to recruitment | Clinical Trial | GUH: Professor Maccon Keane SUH: Dr Michael Martin | GrainneB.McDonnell@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/ember-4/ | Results not yet available |
| GUH | Telemedicine | ECANS | Joint Action on strengthening eHealth including telemedicine and telemonitoring for health care systems for cancer prevention and care - eCAN | Closed to recruitment | Clinical Investigation | Professor Aoife Lowery | Dorota.Matczuk@hse.ie | 091- 524222 | | Results not yet available |

| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigator | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------------|--------------------------|-----------------------------------|--|-----------------------|---------------------------|---|---|----------------|--|-------------------------------|
| GUH | Myeloma | CPD Dara | Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD- DARA) in Patients With Relapsed/Refractory Multiple Myeloma. (The CPD-DARA Study) | Closed to recruitment | Clincial Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT04667663 | Results not yet available |
| GUH | CLL | CLL17 | A phase 3 multicentre, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus ixed-duration venetoclax plus ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) | Closed to recruitment | Clinical Trial | Professor Amjad Hayat | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT04608318 | Results not yet available |
| GUH | Lymphoma | Chronos | A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin's lymphoma (iNHL) – CHRONOS-3 | Closed to recruitment | Clinical Trial | Professor Amjad Hayat | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT02367040 | Results not yet available |
| GUH | Myeloma | CC-220-MM- 002 Excaliber | A phase 3, randomised, multicentre, open-label study comparing iberdomide, daratumumab and dexamethasone (lberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in subjects with relapsed or refractory multiple myeloma (RRMM) | Open to recruitment | Clinical Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/excaliber-rrmm/ | Results not yet available |
| GUH | Flow cytometry | Sparrow | Collection and Processing of Peripheral Blood (PB) Specimens from healthy volunteers for Analytical Performance Evaluation of the BD FACSLyricTM Flow Cytometer Instrument | Open to recruitment | Clinical Investigation | Professor Janusz Krawczyk | Shikha.Bakshi@hse.ie | 091- 524222 | n/a | Results not yet available |
| GUH SUH | Weight Loss in Cancer | CARes/ART2 7.13- 100/Artelo | A phase 1/2 trial of the synthetic cannabinoid ART27.13 in patients with cancer anorexia and weight loss | Open to recruitment | Clinical Trial | Sligo: Dr Michael Martin Galway: Prof Dympna Waldron Galway | Sligo: Margaret1.Burke@hse.ie Galway: marian.jennings@hse.ie | 091- 524222 | https://www.cancertrials.ie/ct i-trials/cares-the-cancer- appetite-recovery-study/ | Results not yet available |
| GUH | Breast | CAMBRIA 2 | A phase 3 open label randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER+/HER2- early breast cancer and an interrnediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease | To open soon | Clinical trial | Professor Maccon Keane | alyssa.paz@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05952557 | Results not yet available |

| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigat or | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------------|--|---|---|--------------------------|---|---------------------------------|---|----------------|--|-------------------------------|
| GUH | Myeloma | CA057-001 Successor | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) | Open to recruitment | Clinical Trial | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05519085 | Results not yet available |
| GUH | Healthy volunteer | Bone Marrow Projects visicort BMR | Tissue Procurement for GMP Validation and Research | Open to recruitment | Observational with radiology or blood tests | Professor Janusz Krawczyk | michelleb.hennessy@hse.ie | 091- 524222 | | Results not yet available |
| GUH | Lymphoma | Beigene | Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation | Closed to recruitment | Clinical trial | Professor Amjad Hayat | michelleb.hennessy@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT04002297 | Results not yet available |
| GUH | Breast | ATNEC | Axillary Management in cT1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC) | Open to recruitment | Clinical Investigation | Professor Aoife Lowery | GrainneB.McDonnell@hse.ie | 091- 524222 | | Results not yet available |
| GUH SUH | Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancers | GLORIOSA -ENGOT- OV76 | Randomized Multicenter, Open-label, Phase 3 Study of BevacizumabnWith or Without Mirvetuximab Soravtansine for Patients with FRα–Positive Recurrent PlatinumSensitive Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancers Who Have not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab | Open to recruitment | Clinical Trial | Dr Michael McCarthy | Galway: marian.jennings@hse.ie Sligo: Margaret1.Burke@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05445778 | Results not yet available |
| GUH | Underserved population | Cancer and Disabilities | A Prospective Study to Identify the challenges faced by Irish Healthcare Professionals in the delivery of cancer services to people with intellectual disabilities | Closed to recruitment | Observational | Dr Veronica McInerney | veronica.mcinerney@universit yofgalway.ie | 091- 524222 | | Results not yet available |
| GUH | Breast | Oral AntiCancer Treatments and telemedicine | A Review of Patients Prescribed Oral Anticancer Treatment for Advanced Breast Cancer- Is there a Role for Telemedicine | Open to recruitment | Observational | Dr Veronica McInerney | veronica.mcinerney@universit yofgalway.ie | 091- 524222 | | Results not yet available |

| Site | Health Area | Brief Title | Study Title | Recruitment Status | Study Type | Principal Investigat or | For more Information please contact Researcher | Phone | For further Information cancertrial.ie | Study results available |
|------|----------------|--------------------------------------|--|-----------------------|----------------|---|--|----------------|--|-------------------------------|
| GUH | Lung | Mirati 007 | A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation | To open soon | Clinical Trial | Dr Silvie Blazkova | marian.jennings@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT04613596 | Results not yet available |
| GUH | Lung | Harmonni | A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous NSCLC (HARMONi-3) | To open soon | Clinical Trial | Dr Silvie Blazkova | marian.jennings@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05899608 | Results not yet available |
| GUH | Breast | Destiny-15 DS8201- 0001-CSI-MA | A Multicenter, Global, Interventional, Open label Study of Trastuzumab Deruxtecan (T-DXd), an Anti HER2 Antibody Drug Conjugate (ADC), in Subjects who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (BC) (DESTINY-Breast15) | To open soon | Clinical Trial | Professor Maccon Keane | alyssa.paz@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05950945 | Results not yet available |
| GUH | Breast | MK2870-012 | MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery | To open soon | Clinical Trial | Professor Maccon Keane | alyssa.paz@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT06393374 | Results not yet available |
| GUH | Breast | PreCoopera | IBCSG 67-22 PREcoopERA A Window-of- Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER- positive/HER2- | Open to recruitment | Clinical Trial | Prof Maccon Keane and Prof Aoife Lowery | olive.forde@hse.ie | 091- 524222 | https://clinicaltrials.gov/study /NCT05896566 | Results not yet available |